clinical trial · NCT01291511
Relapse Prevention Study in Patients With Schizophrenia
SchizophreniaIloperidonePlacebo
brief summary
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
started
Feb 1, 2011
primary completion
Mar 1, 2014
completion
Mar 1, 2015
last updated
Jul 17, 2023
official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Dose Iloperidone or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weeks of Open-label Extension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol